3 research outputs found
Inhibiting Degranulation in Immune Cell Signaling Pathways
Allergies are a pervasive issue and require novel ways of alleviating symptoms. Existing treatments are focused on symptom management and immunotherapy, but there is also potential to target the molecules involved in the downstream pathway, particularly the PLCĪ³ enzymatic pathway. Our research aimed to identify important target molecules involved in this pathway that result in the degranulation of mast cells. We intended to inhibit these molecules in order to hinder mast cell degranulation and therefore prevent allergic symptoms. Our results were tested and measured in MC/9 (mouse mast cell) and RBL-2H3 (rat basophilic) cell lines with multiple cell degranulation assays such as the beta-hexosaminidase and tryptase assay. The results were evaluated based on the comparative effect as well as specificity of inhibitors on mast cell degranulation. We aim to find the most ideal inhibitor for the PLCĪ³, SK, S1P2 enzymatic pathways in the signalling cascade in order to most effectively reduce degranulation and thus reduce the allergic response.Mosser Lab, Gemstone Honors Program, and our generous LaunchUMD donor
COMPUTATIONAL SCREENING FOR NOVEL INHIBITORS OF PROTEINS IN THE MAST CELL DEGRANULATION PATHWAY
Gemstone Team CASCADEAllergies are a pervasive issue and require novel ways of alleviating symptoms.
Existing treatments focus on symptom management and immunotherapy in response to
an allergic reaction. However, there is also the potential for prophylactic treatment that
inhibits molecules involved in the mast cell degranulation pathway, which causes allergic
symptoms. We identified potential target proteins downstream of this pathway including
PKC, PLCĪ³, and PI3K isoforms, the activation of which results in the degranulation of
mast cells. We computationally modeled protein-inhibitor binding interactions and
identified inhibitors with the predicted highest binding affinity to the target pathway
proteins. For the most efficient inhibitors, we extended our analysis by construction of
analogs to determine which chemical properties of the inhibitors contributed to the
highest binding affinity. The identified possible inhibitors have the potential to hinder
mast cell degranulation, limit histamine and cytokine release, and therefore prevent
allergic symptoms, making them ideal targets for future pharmacology research
Initial Assessment of SARS-CoV-2 Omicron Variant in Exhaled Breath Aerosol
From December 16 through 21 of 2021, we collected exhaled breath aerosol (EBA) from five members of a University campus community infected with SARS-CoV-2 viruses displaying an S-gene target failure when assayed using the TaqPath COVID-19 Real Time PCR Assay (Thermo Scientific)